全文获取类型
收费全文 | 3254篇 |
免费 | 260篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 66篇 |
妇产科学 | 37篇 |
基础医学 | 605篇 |
口腔科学 | 24篇 |
临床医学 | 397篇 |
内科学 | 805篇 |
皮肤病学 | 78篇 |
神经病学 | 264篇 |
特种医学 | 39篇 |
外科学 | 340篇 |
综合类 | 3篇 |
一般理论 | 1篇 |
预防医学 | 249篇 |
眼科学 | 50篇 |
药学 | 251篇 |
中国医学 | 1篇 |
肿瘤学 | 308篇 |
出版年
2023年 | 26篇 |
2022年 | 43篇 |
2021年 | 110篇 |
2020年 | 58篇 |
2019年 | 86篇 |
2018年 | 114篇 |
2017年 | 67篇 |
2016年 | 94篇 |
2015年 | 104篇 |
2014年 | 130篇 |
2013年 | 176篇 |
2012年 | 276篇 |
2011年 | 310篇 |
2010年 | 159篇 |
2009年 | 149篇 |
2008年 | 251篇 |
2007年 | 241篇 |
2006年 | 236篇 |
2005年 | 244篇 |
2004年 | 216篇 |
2003年 | 171篇 |
2002年 | 165篇 |
2001年 | 13篇 |
2000年 | 5篇 |
1999年 | 12篇 |
1998年 | 20篇 |
1997年 | 17篇 |
1996年 | 8篇 |
1995年 | 18篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有3531条查询结果,搜索用时 15 毫秒
41.
Véronique Diéras Jacques Bonneterre Valérie Laurence Marian Degardin Jean-Yves Pierga Marie-Edith Bonneterre Sandrine Marreaud Denis Lacombe Pierre Fumoleau 《Clinical cancer research》2005,11(17):6256-6260
PURPOSE: The purpose of this study was to investigate the safety and tolerability of MS209, a potent inhibitor of P-glycoprotein, when given in combination with docetaxel and to determine whether MS209 affects docetaxel pharmacokinetics. EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were eligible for this phase I trial. Docetaxel as 1-hour infusion was given alone during the first cycle. MS209 was introduced as of cycle 2 and given orally 30 minutes after docetaxel infusion. The dose escalation scheme followed a modified Fibonacci model with six steps (docetaxel, 60-100 mg/m2 and MS209, 300-1,200 mg per body). RESULTS: A total of 30 patients were treated at five dose levels. Dose-limiting toxicities were febrile neutropenia, infection, stomatitis, dysphagia, and fatigue. The maximum tolerated dose was reached at level 5 (docetaxel, 80-MS: 1,200). Pharmacokinetic analysis failed to show a strong pharmacokinetic interaction between the two compounds, but at the highest dose levels, there is a trend to an increase of docetaxel AUC when this agent is given in combination with MS209. CONCLUSION: MS209 can be given in combination with docetaxel, with limited effect on docetaxel toxicity or pharmacokinetics. 相似文献
42.
Sandrine Bourgeois Richard Harvey Professor Elias Fattal 《American Journal of Drug Delivery》2005,3(3):171-204
Most therapeutic peptides and proteins are administered via the parenteral route, which presents numerous drawbacks and limitations. To overcome these drawbacks, alternative administration routes, such as oral or mucosal routes, have been investigated. The oral route presents a series of attractive advantages for the administration of therapeutic compounds, such as the avoidance of the pain and discomfort associated with injections, good patient compliance, and being less expensive to produce. However, oral administration of peptides, proteins, or nucleic acids also presents several difficulties because of their instability in the upper gastrointestinal (GI) tract and their poor transport across biologic membranes. Among the various approaches developed to improve the oral delivery of peptides, proteins, or nucleic acids, specific delivery to the colon has attracted a lot of interest because of its potential for the local treatment of colonic diseases, systemic delivery of poorly absorbed drugs, and vaccine delivery. Numerous pharmaceutical approaches described in this review have been exploited for the development of colon-targeted drug delivery systems using various concepts, such as pH-dependent, time-dependent, pressure-controlled, or bacterially triggered delivery systems. The action of the pH-dependent delivery systems is based on pH differences between the stomach and the ileum. Time-dependent delivery systems are based on the transit time of pharmaceutical dosage forms in the GI tract, drug release being delayed until they reach the colon. A combination of pH- and time-dependent delivery systems has also been described to avoid the drawbacks of both strategies. The pressure-controlled delivery concept exploits the physiologic luminal pressure of the colon as the driving force for site-specific delivery of drugs. Finally, bacterially triggered delivery systems exploit the enormous diversity of enzymatic activity associated with the colonic microflora. Bacterially triggered delivery systems are generally composed of polymers, which are specifically degraded by colonic enzymes of microbial origin. These polymers have been used to form prodrugs with the drug moiety, as coating materials for the drug core, or as embedding media to entrap the drug into matrix or hydrogel systems. Each of these concepts has advantages and limitations. They present varied colonic specificity and, among them, bacterially triggered delivery systems in particular show the greatest potential for colonic delivery of peptides, proteins, and nucleic acids. 相似文献
43.
44.
Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
45.
46.
Involving children and young people in clinical research through the forum of a European Young Persons’ Advisory Group: needs and challenges
下载免费PDF全文
![点击此处可从《Fundamental & clinical pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Segolene Gaillard Salma Malik Jenny Preston Begonya Nafria Escalera Pamela Dicks Nathalie Touil Sandrine Mardirossian Joana Claverol‐Torres Behrouz Kassaï 《Fundamental & clinical pharmacology》2018,32(4):357-362
Children and young people are seen as fundamental to the design and delivery of clinical research as active and reflective participants. In Europe, involvement of children and young people in clinical research is promoted extensively in order to engage young people in research as partners and to give them a voice to raise their own issues or opinions and for their involvement in planning and decision making in addition to learning research skills. Children and young people can be trained in clinical research through participation in young person advisory groups (YPAGs). Members of YPAGs assist other children and young people to learn about clinical research and share their experience and point of view with researchers, thereby possibly influencing all phases of research including the development and prioritization of research questions, design and methods, recruitment plans, and strategies for results dissemination. In the long term, the expansion of YPAGs in Europe will serve as a driving force for refining pediatric clinical research. It will help in a better definition of research projects according to the patients’ needs. Furthermore, direct engagement of children and young people in research will be favorable to both researchers and young people. 相似文献
47.
48.
Amélie Huynh Le Maux Bernadette Pignol Delphine Behr-Roussel Jean-Luc Blachon Pierre-Etienne Chabrier Sandrine Compagnie Philippe Picaut Jacques Bernabé Fran?ois Giuliano Pierre Denys 《Toxins》2015,7(12):5462-5471
Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder. 相似文献
49.
50.
Hind Hamzeh-Cognasse Philippe Berthelot Bernard Tardy Bruno Pozzetto Thomas Bourlet Sandrine Laradi 《Platelets》2018,29(6):533-540
In addition to their haemostatic role and function in the repair of damaged vascular epithelium, platelets play a defensive role in innate immunity, having the capacity to produce and secrete various anti-infectious factors, as well as cytokines, chemokines and related products, to interact with other immune cells to modulate immune responses to pathogens. Thus, it is now widely acknowledged that platelets participate in inflammatory processes and infection resolution, most notably by expressing and using receptors to bind infectious pathogen moieties and contributing to pathogen clearance. The ability of platelets to sense external danger signals relates to the expression of certain innate immunity receptors, such as toll-like receptors (TLRs), and the activation of efficient cell signalling machinery. TLR engagement triggers platelet response, which results in adapted degranulation according to: the type of TLR engaged, the nature of the ligand and the milieu; together, the TLR-mediated event and other signalling events may be followed by aggregation. Platelets thus use complex tools to mediate a whole range of functions upon sensing danger. By linking the inflammatory and haemostatic platelet response to infection, TLRs play a central role. The extent of the inflammatory response to pathogen clearance is still a debatable issue and is discussed in this short review. 相似文献